SCHEMBL876009

SCHEMBL876009

N#Cc1cncc(Oc2ccc(C=O)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PARP3 Q9Y6F1 1/20 0.41
CYP3A4 P08684 2/20 0.40
VEGFA P15692 2/20 0.40
PPARG P37231 1/20 0.40
EPAS1 Q99814 3/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
GRM5 P41594 1/20 0.38
RAF1 P04049 1/20 0.38
SCN9A Q15858 1/20 0.37
P2RX3 P56373 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875755 0.82 SLC22A12 (0.50) ALDH1A1SMN1; SMN2CYP3A4VEGFAPPARG
SCHEMBL875893 0.81 VEGFA (0.43) CYP19A1CYP3A4VEGFAPPARGEPAS1
SCHEMBL875569 0.81 SLC22A12 (0.44) CYP3A4VEGFAEPAS1
SCHEMBL505351 0.80 PARP10 (0.53) CYP19A1KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL2425876 0.80 CYP3A4 (0.50) CYP19A1KDM4EALDH1A1CYP3A4VEGFA
SCHEMBL6821689 0.79 CYP19A1 (0.56) CYP19A1ALDH1A1SMN1; SMN2CYP3A4VEGFA
SCHEMBL3163442 0.78 PGR (0.47) CYP19A1KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL875005 0.76 PPARG (0.48) KDM4EALDH1A1LMNASMN1; SMN2PARP10
SCHEMBL876496 0.76 LTA4H (0.46) CYP19A1CYP3A4VEGFAPPARGEPAS1
SCHEMBL31586111 0.75 RAF1 (0.50) RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LTD (GB) 2014-12-25 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
US-8871928-B2 Tricyclic compounds, preparation methods, and their uses GLAXO GROUP LIMITED (GB) 2014-10-28 US disclosed
EP-2619203-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES Glaxo Group Limited (GB) 2013-07-31 EP disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378487-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 CYP19A1 998/4885KDM4E 4272/4885ALDH1A1 3675/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 CYP19A1 998/4885KDM4E 4272/4885ALDH1A1 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.